Text Size

LOSS- Louisiana Obese Subjects Study

This study has been terminated.
(ethical issues of continuing control group without treatment)
Sponsor:
Collaborator:
Louisiana Office of Group Benefits
Information provided by:
Pennington Biomedical Research Center
ClinicalTrials.gov Identifier:
NCT00115063
First received: June 20, 2005
Last updated: June 7, 2010
Last verified: June 2010
History of Changes
  Purpose

LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for individuals with extreme obesity (body mass index [BMI] 40-60 kg/m2). The intensive medical treatment is designed to produce 25% weight loss from baseline and to maintain at least 20% weight loss from baseline. The intensive medical treatment is compared to a usual care treatment model where individuals utilize self directed approaches to weight loss. The active treatment period is three years, followed by two years of observation.


Condition Intervention Phase
Obesity
 Behavioral: group sessions
Drug: sibutramine, orlistat, diethylpropion
Behavioral: Low Calorie Diet, Health One
Other: Intensive Medical Combination Therapy for Obesity
Other: Control Condition
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Loss - Louisiana Obese Subjects Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pennington Biomedical Research Center:

Primary Outcome Measures:
  • Percent Change From Baseline Weight [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Weight From Baseline in Kilograms (kg) [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: No ]
  • Change in Blood Pressure [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: Yes ]
  • Percent Change in Blood Tests- Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Triglycerides and Uric Acid [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: Yes ]
  • Change in Fasting Plasma Glucose (FPG) in Milligrams Per Deciliter (mg/dL) [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: Yes ]
  • Change in Duke Activity Status Index (DASI) Questionnaire Score [ Time Frame: Baseline, 2 years ] [ Designated as safety issue: No ]
    The DASI was used to access changes in fuctional capacity during the study. The highest score possible is 58.2 and the lowest is 0. The score for each individual question varied depending on the intensity of the activity being evaluated. The higher the score, the more physically active a person is to this set of activities of daily living questions.


Enrollment: 390
Study Start Date: July 2005
Study Completion Date: January 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a "Tool Box" approach
 Behavioral: group sessions
group sessions lead by a trained primary care clinic employee
Drug: sibutramine, orlistat, diethylpropion
dosage modified according to package insert instructions at discretion of primary care physicians
Behavioral: Low Calorie Diet, Health One
liquid diet for 8-12 weeks to induce weight loss
Other: Intensive Medical Combination Therapy for Obesity
Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a "Treatment Toolbox".
Active Comparator: 2
Access to Weight Loss Informational Website sponsored by the Mayo Clinic
 Other: Control Condition
Access to the Mayo Clinic weight management website and usual care from the primary care physician

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant in the Exclusive Provider Organization (EPO), Managed Care Organization (MCO) and Preferred Provider Organization (PPO) programs of the Louisiana State Employees Group Benefits Health Insurance
  • Agree to travel for treatment to the assigned study site
  • Agree to randomized treatment assignment
  • Male and females age 20-60 years
  • Body Mass Index >40kg/m2 but < 60 kg/m2
  • Females must be non-pregnant and using an approved contraception method
  • Complete Blood Count (CBC): normal hematocrit, white count and platelet count, unless waived by Principal Investigator (PI)
  • Uric Acid <9.0 mg/dl
  • Normal Creatinine
  • Normal Thyroid Stimulating Hormone (TSH)
  • Negative urine pregnancy test for women of childbearing potential
  • Able to give written informed consent
  • Able to comply with study procedures

Exclusion Criteria:

Factors that may limit adherence to interventions or affect conduct of the trial:

  • Unable or unwilling to give informed consent or communicate with local study staff
  • Hospitalization for psychiatric illness or substance use/abuse within the past year
  • Self-report of alcohol or substance abuse within the past twelve months
  • Current major depressive episode or history of suicidal behaviors
  • Endorsement of significant recent suicidal ideation (as determined by PI)
  • Travel plans that do not permit participation
  • History of prior bariatric surgery, small bowel resection, or extensive bowel resection
  • Current use of chronic systemic corticosteroids, appetite suppressants, antipsychotic medication, herbal medications for weight loss or any medication not approved by the PI.
  • Another member of the household is a participant or staff member in the study
  • History of eating disorder such as anorexia nervosa, bulimia, or binge eating
  • Diagnosis of schizophrenia, other psychotic disorders, bipolar disorder, or personality disorder (as determined by the PI)
  • Currently pregnant or nursing or plans to become pregnant in the next five years
  • Except for non-melanoma skin cancer, cancer requiring treatment in the past five years, unless the prognosis is excellent
  • Self report of Human Immunodeficiency Virus (HIV) positive, hepatitis C or active tuberculosis
  • Cardiovascular disease event within the past year
  • Severe congestive heart failure (New York Heart Association [NYHA] Functional Class III, IV)
  • Second degree or greater heart block
  • Blood Pressure >160 systolic or >100 diastolic on two consecutive visits, unless treated and re-screened
  • Based upon responses to psychological screening or an interview, patients may be excluded by the study psychologist.
  • Other medical, psychiatric, or behavioral limitations that in the judgment of the investigator may interfere with study participation or the ability to follow the intervention protocol.
  • Pregnancy is to be avoided during the study. Women who have not had a hysterectomy or oophorectomy must have a negative urine pregnancy test result at screening. Women of childbearing potential will be allowed to participate if they have undergone tubal ligation, or use one of the following types of contraception: properly used condom or diaphragm, oral contraceptives, hormonal implant, or intrauterine device (IUD). Sexual abstinence may constitute an acceptable birth control method for this study with investigator approval. Women with male partners who have had a successful vasectomy (more than one year of unprotected sexual intercourse without pregnancy) are not required to use additional birth control methods as long as the relationship remains exclusive, and the woman agrees to use an approved contraception method with any other male partner. Questions regarding individual patient contraceptive practices should be directed to the Principal Investigator.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00115063

Locations
United States, Louisiana
Pennington Management of Clinical Trials
Baton Rouge, Louisiana, United States, 70808
Sponsors and Collaborators
Pennington Biomedical Research Center
Louisiana Office of Group Benefits
Investigators
Principal Investigator: Donna H Ryan, MD Pennington Biomedical Research Center
  More Information

Additional Information:
Pennington Biomedical Research Center home page  This link exits the ClinicalTrials.gov site

No publications provided by Pennington Biomedical Research Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Donna H Ryan, MD, Pennington Biomedical Research Center
ClinicalTrials.gov Identifier: NCT00115063     History of Changes
Other Study ID Numbers: PBRC - OGB -1
Study First Received: June 20, 2005
Results First Received: March 1, 2010
Last Updated: June 7, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Pennington Biomedical Research Center:
obesity
Low Calorie Diet
Obesity Pharmacotherapy
Pragmatic Clinical Trial

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Diethylpropion
Sibutramine
Orlistat
 Appetite Depressants
Anti-Obesity Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 23, 2013